111 related articles for article (PubMed ID: 9712349)
21. Role of polymorphic residues of human leucocyte antigen-DR molecules on the binding of human immunodeficiency virus peptides.
Jurcevic S; Praud C; Coppin HL; Bertrand A; Ricard S; Thomsen M; Lakhdar-Ghazal F; De Preval C
Immunology; 1996 Mar; 87(3):414-20. PubMed ID: 8778027
[TBL] [Abstract][Full Text] [Related]
22. Cutting edge: TCR contacts as anchors: effects on affinity and HLA-DM stability.
Anderson MW; Gorski J
J Immunol; 2003 Dec; 171(11):5683-7. PubMed ID: 14634075
[TBL] [Abstract][Full Text] [Related]
23. The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules.
Wu S; Gorski J
Mol Immunol; 1996; 33(4-5):371-7. PubMed ID: 8676888
[TBL] [Abstract][Full Text] [Related]
24. Identification of HLA-DR1 beta chain residues critical for binding staphylococcal enterotoxins A and E.
Karp DR; Long EO
J Exp Med; 1992 Feb; 175(2):415-24. PubMed ID: 1370684
[TBL] [Abstract][Full Text] [Related]
25. Peptide linkage to the α-subunit of MHCII creates a stably inverted antigen presentation complex.
Schlundt A; Günther S; Sticht J; Wieczorek M; Roske Y; Heinemann U; Freund C
J Mol Biol; 2012 Oct; 423(3):294-302. PubMed ID: 22820093
[TBL] [Abstract][Full Text] [Related]
26. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size.
Chicz RM; Urban RG; Lane WS; Gorga JC; Stern LJ; Vignali DA; Strominger JL
Nature; 1992 Aug; 358(6389):764-8. PubMed ID: 1380674
[TBL] [Abstract][Full Text] [Related]
27. In the absence of the invariant chain, HLA-DR molecules display a distinct array of peptides which is influenced by the presence or absence of HLA-DM.
Lightstone L; Hargreaves R; Bobek G; Peterson M; Aichinger G; Lombardi G; Lechler R
Proc Natl Acad Sci U S A; 1997 May; 94(11):5772-7. PubMed ID: 9159149
[TBL] [Abstract][Full Text] [Related]
28. Antigen presentation of mycobacterial peptides to human T cell clones can be immunomodulated by adding an MHC-specific inhibitor.
Méndez-Samperio P
Cell Immunol; 1993 Apr; 148(1):1-9. PubMed ID: 8495481
[TBL] [Abstract][Full Text] [Related]
29. Invariant chains with the class II binding site replaced by a sequence from influenza virus matrix protein constrain low-affinity sequences to MHC II presentation.
Carstens C; Newman DK; Bohlen H; König A; Koch N
Int Immunol; 2000 Nov; 12(11):1561-8. PubMed ID: 11058576
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers.
Busch R; Pashine A; Garcia KC; Mellins ED
J Immunol Methods; 2002 May; 263(1-2):111-21. PubMed ID: 12009208
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects on HLA-DR1-specific T-cell activation by influenza virus haemagglutinin-derived peptides.
Li X; Li R; Li Z
Tissue Antigens; 2006 Jan; 67(1):45-52. PubMed ID: 16451200
[TBL] [Abstract][Full Text] [Related]
32. Enhanced catalytic action of HLA-DM on the exchange of peptides lacking backbone hydrogen bonds between their N-terminal region and the MHC class II alpha-chain.
Stratikos E; Wiley DC; Stern LJ
J Immunol; 2004 Jan; 172(2):1109-17. PubMed ID: 14707085
[TBL] [Abstract][Full Text] [Related]
33. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides.
Ishioka GY; Adorini L; Guery JC; Gaeta FC; LaFond R; Alexander J; Powell MF; Sette A; Grey HM
J Immunol; 1994 May; 152(9):4310-9. PubMed ID: 8157954
[TBL] [Abstract][Full Text] [Related]
34. Functional evidence for the recognition of endogenous peptides by autoreactive T cell clones.
Rees AD; Lombardi G; Scoging A; Barber L; Mitchell D; Lamb J; Lechler R
Int Immunol; 1989; 1(6):624-30. PubMed ID: 2489049
[TBL] [Abstract][Full Text] [Related]
35. [The inhibitory effect of hyporesponsive peptide on human leukocyte antigen-DRbeta1 specific T cell activation].
Zhou Q; Cheng YJ; Li ZG; Zhou WH; Lu HS
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1505-9. PubMed ID: 14521731
[TBL] [Abstract][Full Text] [Related]
36. Tetraspan microdomains distinct from lipid rafts enrich select peptide-MHC class II complexes.
Kropshofer H; Spindeldreher S; Röhn TA; Platania N; Grygar C; Daniel N; Wölpl A; Langen H; Horejsi V; Vogt AB
Nat Immunol; 2002 Jan; 3(1):61-8. PubMed ID: 11743588
[TBL] [Abstract][Full Text] [Related]
37. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
38. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding.
Thibodeau J; Cloutier I; Lavoie PM; Labrecque N; Mourad W; Jardetzky T; Sékaly RP
Science; 1994 Dec; 266(5192):1874-8. PubMed ID: 7997881
[TBL] [Abstract][Full Text] [Related]
39. HLA-DR-restricted presentation of purified myelin basic protein is independent of intracellular processing.
Vergelli M; Pinet V; Vogt AB; Kalbus M; Malnati M; Riccio P; Long EO; Martin R
Eur J Immunol; 1997 Apr; 27(4):941-51. PubMed ID: 9130648
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of the HLA-DM-HLA-DR1 complex defines mechanisms for rapid peptide selection.
Pos W; Sethi DK; Call MJ; Schulze MS; Anders AK; Pyrdol J; Wucherpfennig KW
Cell; 2012 Dec; 151(7):1557-68. PubMed ID: 23260142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
